URRENT PINION Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal’s Section Editors for this issue. SECTION EDITORS He is also Chair of the Steering Committee of the recently launchedCentral EuropeanInitiative against Robert Pirker Lung Cancer. Robert Pirker has received several sci- entific awardsandhasbeenamemberofESMO,ASCO and other scientific societies for many years. Robert Pirker is currently Profes- sor of Medicine and Program Director for Lung Cancer at the Reinhard Dummer Department of Medicine I, Medi- cal University of Vienna, Austria. He obtained a master’s degree in Professor Reinhard Dummer is Biochemistry in 1978 and his Professor of the University of Zur- medical degree in 1979 from the ich and Vice-Chairman of the University of Vienna. Robert Department of Dermatology in Pirker trained in Internal Medicine, Hemato- the University Hospital of Zurich, Oncology and Nuclear Medicine at the University Switzerland and is a key thought of Vienna. He also worked as NIH Visiting Fellow at leader in worldwide cutaneous the Laboratory of Molecular Biology (Chief: Dr Ira oncology. Currently he is heading Pastan), National Cancer Institute, Bethesda, MD, of the Skin Cancer Unit and the USA (1983–86). Clinical Trial Unit of the Department of Dermatol- He specialises in Hemato-Oncology. His ogy. Professor Dummer began his medical education research focuses on drug resistance mechanisms in in haematology and oncology before successfully patients with cancer, chemotherapy and targeted completing his dermatology residency in Wurzburg, Germany, and Zurich € in 1992. therapy of lung cancer, predictive factors in lung He is Board Certified in allergology, clinical cancer, and anaemia management in patients with cancer. As a member of the IALT-Bio and LACE-Bio immunology, dermatology and dermatopathology. groups, he has been involved in the characterization Professor Dummer’s principal research interests of predictive factors with regard to adjuvant chemo- are molecular biology, immunology and immuno- therapy in patients with completely resected therapy of cutaneous malignancies, including NSCLC. He was also the world-wide Co-ordinating cutaneous lymphomas and melanomas. He has pub- Investigator of the FLEX trial. lished more than 677 papers with a cumula- Robert Pirker has published more than 150 tive impact factor of more than 5787. He was articles, reviews or book chapters. He is an Editorial Past-President of the Melanoma Project Group of Board Member of Lung Cancer, ESMO Faculty Mem- the Swiss Institute for Applied Cancer Research since ber on Chest Tumors, and has been a member includ- 1999–2016, is a member of German National ing chair of the IASLC Education Committee. He was Academy of Sciences (Leopoldina) and is past board Congress President of the 8th Central European Lung member of the Society for Melanoma Research and Cancer Congress in 2002 and Chair of the Scientific Past-President of the International Society for Cuta- Committee of the European Multidisciplinary Con- neous Lymphomas. ference on Thoracic Oncology in 2009. He will be He is a founding and board member of the Euro- Congress President of the 14th Central European pean Association of Dermato-Oncology (EADO), Lung Cancer Congress in 2014 and the 17th World ESMO, EATI, URPP and past President of the Euro- Congress on Lung Cancer in 2016 in Vienna, Austria. pean Society for Dermatological Research (ESDR). 1040-8746 Copyright 2018 Wolters Kluwer Health, Inc. All rights reserved. www.co-oncology.com Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Current Opinion in Oncology – Wolters Kluwer Health
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud